Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Enhanced anti-tumor activity by the combination of the natural compounds (-)-epigallocatechin-3-gallate and luteolin.
Journal: The Journal of biological chemistry
Published: November 06, 2025
Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer.
Journal: Epidemiology and health
Published: June 11, 2018
Could valproic acid be an effective anticancer agent? The evidence so far.
Journal: Expert review of anticancer therapy
Published: July 15, 2014
Aberrant promoter methylation of caveolin-1 is associated with favorable response to taxane-platinum combination chemotherapy in advanced NSCLC.
Journal: PloS one
Published: July 13, 2014
Molecular characteristics of non-small cell lung cancer with reduced CHFR expression in The Cancer Genome Atlas (TCGA) project.
Journal: Respiratory medicine
Published: July 03, 2014
Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer.
Journal: Cancer prevention research (Philadelphia, Pa.)
Published: January 21, 2014
Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine.
Journal: Cancer metastasis reviews
Published: December 31, 2013
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 21, 2013
CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 07, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026